New features in MEK retinopathy

BACKGROUND: The use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic alterations in signal transduction pathways, hence less generalised toxicity. Dabrafenib, a BRAF inhibitor and Trametinib, a MEK inhibitor are two molecularly targeted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyagi, Pallavi, Santiago, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157024/
https://www.ncbi.nlm.nih.gov/pubmed/30255823
http://dx.doi.org/10.1186/s12886-018-0861-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157024/
https://www.ncbi.nlm.nih.gov/pubmed/30255823
http://dx.doi.org/10.1186/s12886-018-0861-8

Ejemplares similares